Patients Coming Off Weight-Loss Injections Regain Weight at a Quadrupled Rate Compared to Those on Conventional Diets

A recent study suggests that individuals who come off blockbuster weight-loss injections like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who end conventional diet and exercise plans.

Findings released in a leading health publication shows that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.

"Individuals buying these drugs should be aware of the potential of rapid weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

This pace of recovery implies a reversion to starting mass in about one and a half years.

Comparing Approaches

The analysis, which examined 37 of trials involving over 9,000 of patients, compared the effects of these new drugs with other pills.

The team note that people who lose weight through dieting typically see a slower weight regain—perhaps 100 grams monthly—after stopping.

The Reason for the Fast Rebound

Experts suggest the mechanism of the injections is key to understanding the amplified weight return.

The injections mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating much more probable."

A Lifelong Condition?

Medical guidelines advise the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.

Professionals argue that, considering the likelihood of weight regain, the treatment might need to be life-long.

This opinion is echoed by drug manufacturers, who note that the results "underscore the long-term character of obesity," similar to managing diseases like high blood pressure.

User Experiences

Users who have discontinued the medication explain a sudden return of appetite.

"It was like something flipping and I was suddenly ravenous," said a patient.

This difficulty is compounded if patients have not established permanent lifestyle or habit changes during treatment.

Growing Use

Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is greater among females compared to men.
• The middle-aged demographic shows the highest level of interest.
• A large proportion access the medications through private healthcare rather than public health services.

Finally, clinicians stress that while these medications are powerful tools for weight loss, they are not a permanent cure and maintained weight loss hinges on combined lifestyle changes.